A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether use of thromboelastography could predict and decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery. Altogether 170 papers were identified using the reported search strategy of which 14 represented the best evidence on the topic. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. We conclude that thromboelastography may be useful in predicting patients who are likely to bleed postoperatively but more importantly, it can guide transfusion therapy algorithms in the bleeding cardiac surgical patient resulting in significant decreases in blood and blood component transfusion requirements. However, the technique remains unvalidated in the eyes of many haematologists and further large studies involving them are required to fully validate its use and to define the 'ideal' treatment algorithm.
Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in the ICVTS w1x.
Three part question
In wadult patients undergoing cardiac surgeryx, does wThromboelastographyx predict or decrease wbleeding and blood product requirementsx.
Clinical scenario
You start work in a new unit which routinely uses thromboelastography to manage coagulopathy and guide treatment with blood component therapy following surgery. As you have no experience of the technique you decide to review the literature to identify whether the technique is actually beneficial in decreasing exposure to allogeneic blood and blood component therapy. 
Search strategy

Search outcome
A total of 170 papers were identified using the reported search of which 14 represented the best evidence on the subject. These studies are summarised below ( Table 1) .
Discussion
Thromboelastography (TEG) is a point-of-care whole blood coagulation monitor which provides information on specific aspects of coagulation including time to production of initial fibrin strands (R-time), time to develop clot (R-time, K-time), rate of fibrin build-up and cross linking (a-angle), maximum clot strength (maximum amplitude-bMA) and measures of fibrinolysis (decreasing amplitude post-MA).
Abnormal TEG data may predict patients who will bleed. Spiess w2x found that TEG correlated well with ACT and blood samples " Abciximab blood loss groups -PFA data -significant somewhat arbitrary vs. platelet function )750 ml and differences for analyser (PFA-100) using -750 ml in 6 h preop ADP PFA epinephrine and ADP coated vs. postop ADP cartridges post-induction of PFA and epinephrine anaesthesia, during CPB after
Comparison of ROTEG PFA (P-0.05) rewarming and post-protamine and PFA-100 data for Blood loss )500 ml Bleeding limit based on administration to predict blood loss groups more vs. loss -500 ml 75th percentile more postop blood loss and less than 75th -significant differences useful percentile in 6 h between ROTEG MA's Data for blood loss )750 ml in on CPB and post-CPB (" 6 h compared to group Abciximab); ROTEG post-CPB; with blood loss -750 ml in 6 h a-angle (" Abciximab); and Demonstrates low PPV post-CPB PFA's with ADP and high NPV and epinephrine (P-0.05) derived from reference values in normal MTD no significant population and there is differences no evidence that they between groups are optimal for study group coagulation profiles and whilst no coagulation test was consistently abnormal the TEG was the most accurate predictor of bleeding. Ereth w4x studied a 'Platelet-activated clotting test' (PACT HemoSTATUS), ACT and clotting studies, and TEG. Whilst PACT sensitivity and specificity was comparable to conventional coagulation tests in predicting blood loss, TEG was more predictive at both blood loss levels. Essell w5x found that whilst the bleeding time and platelet count had sensitivities similar to the TEG, TEG specificity was greater. In addition, they suggested that patients with an abnormal TEG were at increased risk of bleeding but that excessive bleeding in the face of a normal TEG implied surgical bleeding and FFP and platelets should not simply be used empirically. Ti w7x found moderate correlation between TEG parameters, total blood loss and requirements for FFP andy or platelets in their group of 'bleeders'.
In contrast, other studies did not find the TEG to be a useful predictor of blood loss. Nuttall w8x reported that TEG values had a low sensitivity and specificity in predicting 'bleeders'. Dorman w9x compared preoperative coagulation screens to ACTs and TEGs as predictors of blood loss but found no significant relationship between any TEG variable and losses.
A number of studies have used the TEG to guide transfusion management. Avidan w10x Compared TEG to a Laboratory based algorithm. They concluded that whilst blood and blood product usage was significantly more in the laboratory group, there was no statistically significant difference between the study groups. Spiess w11x analysed 1079 patients before and after the introduction of TEG as part of an overall transfusion management strategy. They identified significant changes in their practice with decreased usage of all blood and blood component therapies with the exception of cryoprecipitate. Their re-exploration rate also fell significantly. However, this study probably reflects the effects of education and co-operative behaviour in monitoring changes rather than a true experimental difference between groups.
Two randomised controlled trials have been performed. Shore-Lesserson w13x compared 'TEG-based' and 'conventional' protocols to manage postoperative bleeding. Whilst there was no significant difference in mediastinal tube drainage between the groups, blood and blood component therapy was significantly less in the 'TEG' than in the 'conventional group'. However, the 'TEG protocol' did have more options than the conventional protocol and was also partly dependent on laboratory tests. In addition, blood products were ordered on the basis of a TEG taken at rewarm on cardiopulmonary bypass and given in the presence of continued bleeding following protamine, whereas, the conventional group required post-protamine tests to dictate intervention. This inevitably meant earlier intervention in the TEG group. Royston w14x studied 60 patients who had undergone complex surgery comparing their actual bloodyblood product use to a 'predicted usage' derived from a TEG-based algorithm. 'Predicted' bloodyblood component transfusion was significantly less than 'actual' transfusion. They subsequently used this algorithm comparing it to conventional management in a further 60 patients. Again they demonstrated significantly less bloodyblood component usage in the TEG-based group compared to the conventional 'clinician-directed' group with no excessive mediastinal bleeding. However, this study was designed to identify TEG-evidence of coagulation before physical evidence of microvascular bleeding and the authors acknowledge the fact that their protocol allowed much earlier intervention in the active than in the control limb.
A recent review by Samama w15x has raised concerns that thromboelastography remains an unvalidated technique which fails to achieve the stringent standard quality-control procedures essential in laboratory-based tests, citing absence of a formal standard operating procedure taking into account factors such as gender and pregnancy differences, stability of blood samples, and sampling site. There is also no standardised technique and multiple modifications exist including plain versus heparinase samples; celite, kaolin or tissue factor activation; abximimib (Reopro) modified; modified multi-channel; and ROTEG have been described. Several studies acknowledge that TEG facilitates earlier intervention than standard coagulation tests w10,13,14x thus making true comparisons difficult. Samama et al. conclude their review by suggesting that extended collaborative studies involving haematologists are required to further evaluate and validate thromboelastography w15x.
Clinical bottom line
Thromboelastography can be used to predict bleeding in cardiac surgery, but it can also be used to guide transfusion therapy during postoperative bleeding using appropriate treatment algorithms where its use has been associated with significant decreases in blood and blood component transfusion. However, thromboelastography remains unvalidated compared to other laboratory-based routine coagulation studies and further large controlled studies involving haematology input are required to confirm that its use can be extrapolated to all types of cardiac surgery and also to define the 'ideal' treatment algorithm.
